Organon reports FDA extension of target action date of review of Vtama sNDA
Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...
Monthly Prescribing Reference6d
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.
Organon updates outlook as FDA delays VTAMA label expansion
Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...
Business Wire13d
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Please see our prior announcement for a summary of the transaction terms. VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug ...
New Jersey Business13d
Organon Completes Acquisition of Dermavant
Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...
Pharmaceutical Technology13d
Dermavant acquisition expands Organon’s dermatology portfolio
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.
kalkinemedia14d
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Business Wire IndiaOrganon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition o ...